ProShares Ultra Nasdaq BiotechnologyProShares Ultra Nasdaq BiotechnologyProShares Ultra Nasdaq Biotechnology

ProShares Ultra Nasdaq Biotechnology

No trades
See on Supercharts

Key stats


Assets under management (AUM)
‪70.85 M‬USD
Fund flows (1Y)
‪−19.30 M‬USD
Dividend yield (indicated)
0.91%
Discount/Premium to NAV
1.2%

About ProShares Ultra Nasdaq Biotechnology


Issuer
ProShare Advisors LLC
Brand
ProShares
Expense ratio
0.95%
Home page
Inception date
Apr 7, 2010
Index tracked
NASDAQ / Biotechnology
Management style
Passive
BIB, having been around since 2010, is a leveraged play on the NASDAQ Biotechnology Index (which is also tracked in unlevered form by iShares' IBB), and is heavily focused on NASDAQs biotechnology and pharmaceutical firms with a large-cap bias. The fund gains its 2x leveraged exposure to the index through several financial instruments (i.e. equity securities, derivatives and money-market instruments), and rebalances its exposure daily. Like all geared funds that rebalance daily, BIB is meant for short-term trading since compounding effects over the long-term could create vast differences from expected returnsfor good or for ill.

Classification


Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Pharma, biotech & life sciences
Strategy
Exchange-specific
Weighting scheme
Market cap
Selection criteria
NASDAQ - listed

Returns


1 month3 monthsYear to date1 year3 years5 years
Price performance
NAV total return

What's in the fund


As of November 20, 2024
Exposure type
StocksBonds, Cash & Other
Health Technology
Miscellaneous
Stocks33.10%
Health Technology32.53%
Commercial Services0.44%
Health Services0.13%
Bonds, Cash & Other66.90%
Miscellaneous55.53%
Government6.18%
Cash5.20%
Stock breakdown by region
99%0%
North America99.96%
Europe0.04%
Latin America0.00%
Asia0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings

Dividends


Dividend payout history

Assets under management (AUM)



Fund Flows